1. Germany Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
SynBiotic SE

SynBiotic SE

0.16
EUR
+0.00
(-3.12%)
47.48MMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
3.44
2.78
2
0.81
2.45
- -
Basic EPS, GAAP
- -
-0.05
-0.56
-4.09
-5.97
-2.24
-1.66
- -
Free Cash Flow per Basic Share
- -
-0.04
-2.15
-1.77
-1.83
-0.62
-0.12
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.98
0.93
9.53
9.39
4.93
3.15
3.35
4.93
Tangible Book Value per Share
0.98
0.93
-0.43
-2.1
-0.96
-1.43
-1.23
-0.96
Basic Weighted Avg Shares
2
- -
2
3
4
5
6
4
Sales/Revenue/Turnover
- -
- -
5
9
8
4
14
- -
Operating Margin (%)
- -
- -
-13.23
-132.23
-304.88
-284.82
-73.66
- -
Depreciation Expense
- -
- -
- -
8
19
5
8
- -
Net Income, GAAP
- -
- -
-1
-13
-24
-11
-10
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-16.17
-147.13
-298.35
-275.31
-67.92
- -
Working Capital
- -
- -
-2
6
2
-1
-9
2
LT Debt
- -
- -
- -
3
4
3
5
4
Total Equity
- -
- -
25
37
23
15
21
23
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-5.54
-6.85
-42.07
-84.6
-55.39
-50.27
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'21
Jun'22
Dec'22
ST Debt
- -
- -
1
LT Borrowings
2
- -
3
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
5
Market Capitalization
109
66
47

Working Capital

EUR

•

in mil. unless spec.
Dec'21
Jun'22
Dec'22
Total Current Assets
11
2
8
Cash, Cash Equivalents & STI
5
- -
3
Accounts Receivable, Net
1
- -
- -
Inventories
3
- -
3
Total Current Liabilities
5
1
6
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
2,145.15%
37.06%
Free Cash Flow
- -
5,923.13%
-75.33%
Net Income, GAAP
- -
1,565.55%
-8.6%
Sales/Revenue/Turnover
- -
- -
270.47%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4
2024
- -
- -
14
2025
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-2.24
2024
- -
- -
-1.66
2025
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Daniel Kruse
Full Time Employees
79
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Münsterstraße 336 Düsseldorf NW Germany 40470
IPO Date
May 13, 2021
Website
synbiotic.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
SynBiotic SE (SBX.DE) is a biotechnology company focused on developing and commercializing symbiotic formulations for health and nutrition applications. The company offers a portfolio of symbiotic products, including prebiotic fibers, probiotic strains, and postbiotic compounds; specialized formulations such as SynBiotic-1 for immune support, SynBiotic-2 for gut health, and SynBiotic-3 for metabolic wellness; and contract manufacturing services for custom symbiotic blends targeting dietary supplements and functional foods. Founded in 2018 and headquartered in Planegg, Germany, SynBiotic operates primarily in Europe with distribution partnerships extending to North America and Asia, serving B2B customers in the nutraceutical, pharmaceutical, and food industries. In recent developments, the company announced a strategic partnership with a leading German pharmaceutical firm in early 2025 to co-develop symbiotic therapies for microbiome-based treatments; completed a 15 million euro funding round in Q3 2025 led by existing investors to expand production capacity; and launched SynBiotic-4, a novel postbiotic product line for sports nutrition, marking its entry into the performance health segment.